Cognizant Technology Solutions heads into its Q1 2026 earnings release — reported April 29 — with short sellers at their most aggressive in months and the Street quietly trimming expectations across the board.
Short interest has climbed relentlessly since mid-February. It reached 8.1% of the free float this week, up from around 5.4% in mid-February and a gain of roughly 9% in the past week alone. The month-on-month increase is nearly 19%. That pace of build is the standout story: shorts have added roughly 7 million shares since the start of March, a sustained directional move rather than a single-session dislocation. Days to cover of 7.2 on the official FINRA data underscores how meaningful the position has become relative to typical trading volume. The borrow market has tightened in tandem — cost to borrow rose 32% over the week to 0.49%, its highest level in the 30-day window, though in absolute terms it remains cheap. Availability sits well below historic norms, consistent with a lending market that is absorbing the new short demand without yet flashing a squeeze signal.
Options traders are reading the setup differently. The put/call ratio has collapsed to 0.745 — its 52-week low — and sits nearly 1.3 standard deviations below its 20-day average of 0.881. A month ago, the PCR was north of 1.0. That unwind from defensive hedging into outright call-side positioning is a notable counterweight to the short-side build. Whether options traders are covering ahead of the print or actively positioning for an upside surprise, the contrast with the short interest trend is sharp. Positioning is not singing from the same hymn sheet.
The Street has been uniformly cutting targets. JP Morgan's Tien-Tsin Huang lowered his price objective to $74 from $92 yesterday while holding an Overweight — a 20% target reduction that reflects macro caution rather than a thesis change. Earlier in the month, Guggenheim trimmed to $85, Citigroup cut to $68, and Baird lowered to $72. UBS and Wedbush both sit at Neutral with targets in the $61-$64 range. The consensus remains Buy, and the mean target of $78 implies roughly 42% upside from the current $55.12 — though that gap reflects the severity of the recent de-rating rather than any new conviction from the buy side. The stock has lost nearly 9% over the past week and is down about 8% on the month, broadly in line with close peers: ACN fell 8.6% on the week, EPAM dropped 13.6%, and DXC slid 12.1%. The group is under sector-wide pressure, but Cognizant's short build is outpacing the sector.
The bull case rests on AI-led automation, large deal signings, and improving revenue per employee. The bear case centres on discretionary demand weakness, margin pressure, and limited visibility into the second half of 2026. Factor scores add some nuance: the forward EPS growth percentile ranks in the 93rd percentile for year-on-year increase, and the EV/EBIT score is similarly strong, suggesting the valuation compression has been significant. The PE multiple has contracted roughly 1.1x over 30 days to 9.5x, and the P/B has dropped 0.18x in the same period. Those are not stretched multiples for a business of this quality — but EPS momentum scores in the 29th percentile on the 30-day measure suggest near-term estimate drift is still working against the stock.
Institutional holders reported through March 31 show Pzena adding 2.6 million shares and Capital Research adding 3.3 million — value-oriented buyers absorbing the weakness. GQG Partners disclosed a fresh position of over 8 million shares as of January. These moves provide a floor argument but are not yet sufficient to arrest the short-side momentum.
The next scheduled event is the June 2 earnings call. Between now and then, watch whether the short interest build stalls following the April 29 Q1 release — any stabilisation in that trend, combined with the already-low PCR, would mark the first sign that the bearish positioning is finding its ceiling.
See the live data behind this article on ORTEX.
Open CTSH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
